Navigation Links
Arthrosurface® Hits the 20,000 Implant Milestone
Date:5/24/2010

FRANKLIN, Mass., May 24 /PRNewswire/ -- Arthrosurface, Inc. (www.arthrosurface.com), the developer of inlay joint resurfacing systems, announced the achievement of a significant clinical milestone.  Over 20,000 patients, typically middle aged, have been treated with the various Arthrosurface cartilage resurfacing systems, with the early patients now 6 years post surgery.

"Back in 2003, there was no accepted surgical 'next step' for those patients that had exhausted conservative & biological therapies such as drug injections & microfracture.  With the passing of the 20,000 patient milestone and with more than 98% of the implants still in place, we have achieved our initial goal of providing a less invasive option that would allow patients to go back to an active lifestyle while delaying the need for a joint replacement," commented Steven Ek, COO.

"For very advanced disease in the older aged patient, joint replacement still provides a good option.  However, the baby boomer population has been the silent sufferer.  They have joint pain, limited mobility and all the signs of early articular cartilage damage. In my opinion, a well accepted treatment for early disease in the boomer population does not exist.  Having the Arthrosurface technology as an interim treatment has provided a great new option for these patients," remarked Anthony Schepsis, MD, Professor of Orthopaedic Surgery at Boston University.  "For me and thousands of other surgeons, this system has been a very effective solution for those patients that have failed early treatments and yet are too young for a total joint replacement. The Arthrosurface system has filled this gap in my sports medicine practice."

The Arthrosurface inlay resurfacing technology was developed to treat the young and active patient typically referred to as the baby boomer.  The company's technology uses a family of implants with different shapes and sizes to effectively recreate the patient's joint geometry with an intraoperative 3D mapping instrument set.  Arthrosurface has been a leader in introducing anatomic inlay resurfacing in the knee, shoulder and toe.  The company's focus remains dedicated to early joint resurfacing for the boomer population. The company's systems are indicated and FDA cleared for use in the knee, shoulder, hip and toe.


'/>"/>
SOURCE Arthrosurface, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
2. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
3. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
4. Indevus Pharmaceuticals Reports Positive Results of Phase II Octreotide Implant Trial
5. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
6. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
7. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
8. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
9. Valor Medical Announces First Human Implant of Neucrylate AN(TM) for Treatment of Cerebral Aneurysm
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. First Human Implant of New Archus Orthopedics Facet Replacement System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb 27, 2017 Period October – December 2016 ... Operating result amounted to SEK -16.4 (-6.4) million Result after ... (-0.22) before and after dilution Cash flow from operating activities ... ... 0.4 (0.4) million Operating result amounted to SEK -39.5 (-29.5) ...
(Date:2/24/2017)... , Feb. 24, 2017 Research and ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... a CAGR of around 23.8% over the next decade to reach ... the market estimates and forecasts for all the given segments on ...
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies ... eye market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Dry eye ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... Today, A' Design Awards & Competition ... Social Design Awards. , The 7th A' Social Design Award is open ... worldwide with realized projects and conceptual works. , The first phase of the ...
(Date:2/26/2017)... , ... February 26, 2017 ... ... a new technology standard in staffing, scheduling, and reporting for healthcare organizations. ... predict activity throughout the entire staffing process. StaffBridge technology improves staffing efficiency, ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... newly designed TaskMate Go. Core benefits and advantages built into the home office ... stylish, functional look and feel. Ability to gain the benefits embedded in the ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Liberty University, has officially announced the appointment of Peter A. Bell, DO, MBA, ... Osteopathic Medicine (LUCOM), beginning April 10. Dr. Bell comes to Liberty from ...
(Date:2/24/2017)... ... 2017 , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ... his paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles ... , Schanssema, initially unsure of the career path he wanted to take, found fulfillment ...
Breaking Medicine News(10 mins):